Following the step-change in financial performance announced in the interim results in November, further significant progress was made in December with the announcement of a global pMDI triple programme with Mundipharma, confirmation of the US commercialisation for Ultibro® and Seebri® and the first approval using Vectura’s handheld FOX® smart nebuliser as part of a referenced labelled product.